Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 581

1.

Hippocampal sulcal cavities: prevalence, risk factors and association with cognitive performance. The SMART-Medea study and PREDICT-MR study.

Blom K, Koek HL, van der Graaf Y, Zwartbol MHT, Wisse LEM, Hendrikse J, Biessels GJ, Geerlings MI; SMART Study Group.

Brain Imaging Behav. 2018 Jul 6. doi: 10.1007/s11682-018-9916-y. [Epub ahead of print]

PMID:
29981017
2.

Four ECG left ventricular hypertrophy criteria and the risk of cardiovascular events and mortality in patients with vascular disease.

van Kleef MEAM, Visseren FLJ, Vernooij JWP, Nathoe HM, Cramer MM, Bemelmans RHH, van der Graaf Y, Spiering W; SMART-study group.

J Hypertens. 2018 Jun 6. doi: 10.1097/HJH.0000000000001785. [Epub ahead of print]

PMID:
29878973
3.

Variation in minimum desired cardiovascular disease-free longevity benefit from statin and antihypertensive medications: a cross-sectional study of patient and primary care physician perspectives.

Jaspers NEM, Visseren FLJ, Numans ME, Smulders YM, van Loenen Martinet FA, van der Graaf Y, Dorresteijn JAN.

BMJ Open. 2018 May 26;8(5):e021309. doi: 10.1136/bmjopen-2017-021309.

4.

Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease and Mortality in Individuals With Type 2 Diabetes.

Hanssen NMJ, Westerink J, Scheijen JLJM, van der Graaf Y, Stehouwer CDA, Schalkwijk CG; SMART Study Group.

Diabetes Care. 2018 May 21. pii: dc180159. doi: 10.2337/dc18-0159. [Epub ahead of print]

PMID:
29784769
5.

Limited benefit of haemoglobin glycation index as risk factor for cardiovascular disease in type 2 diabetes patients.

Østergaard HB, Mandrup-Poulsen T, Berkelmans GFN, van der Graaf Y, Visseren FLJ, Westerink J; SMART Study Group.

Diabetes Metab. 2018 May 8. pii: S1262-3636(18)30083-1. doi: 10.1016/j.diabet.2018.04.006. [Epub ahead of print]

PMID:
29784563
6.

Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease.

Kaasenbrood L, Ray KK, Boekholdt SM, Smulders YM, LaRosa JC, Kastelein JJP, van der Graaf Y, Dorresteijn JAN, Visseren FLJ.

Heart. 2018 Apr 5. pii: heartjnl-2017-312510. doi: 10.1136/heartjnl-2017-312510. [Epub ahead of print]

7.

Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes.

Koopal C, Visseren FLJ, Westerink J, van der Graaf Y, Ginsberg HN, Keech AC.

Diabetes Care. 2018 Jun;41(6):1244-1250. doi: 10.2337/dc17-0968. Epub 2018 Feb 22.

PMID:
29472432
8.

Prevalence of Subclinical Coronary Artery Disease Assessed by Coronary Computed Tomography Angiography in 45- to 55-Year-Old Women With a History of Preeclampsia.

Zoet GA, Benschop L, Boersma E, Budde RPJ, Fauser BCJM, van der Graaf Y, de Groot CJM, Maas AHEM, Roeters van Lennep JE, Steegers EAP, Visseren FL, van Rijn BB, Velthuis BK, Franx A; CREW Consortium.

Circulation. 2018 Feb 20;137(8):877-879. doi: 10.1161/CIRCULATIONAHA.117.032695. No abstract available.

PMID:
29459475
9.

Computed Tomography Perfusion Derived Blood-Brain Barrier Permeability Does Not Yet Improve Prediction of Hemorrhagic Transformation.

Horsch AD, Bennink E, van Seeters T, Kappelle LJ, van der Graaf Y, Mali WPTM, de Jong HWAM, Velthuis BK, Dankbaar JW; DUST Investigators.

Cerebrovasc Dis. 2018;45(1-2):26-32. doi: 10.1159/000485043. Epub 2018 Jan 8.

10.

Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease.

Stam-Slob MC, van der Graaf Y, de Boer A, Greving JP, Visseren FLJ.

Int J Cardiol. 2018 Feb 15;253:148-154. doi: 10.1016/j.ijcard.2017.10.080.

PMID:
29306457
11.

Validation of an imaging based cardiovascular risk score in a Scottish population.

Kockelkoren R, Jairam PM, Murchison JT, Debray TPA, Mirsadraee S, van der Graaf Y, Jong PA, van Beek EJR.

Eur J Radiol. 2018 Jan;98:143-149. doi: 10.1016/j.ejrad.2017.11.016. Epub 2017 Nov 23.

PMID:
29279154
12.

Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm: A Meta-analysis.

Harrison SC, Holmes MV, Burgess S, Asselbergs FW, Jones GT, Baas AF, van 't Hof FN, de Bakker PIW, Blankensteijn JD, Powell JT, Saratzis A, de Borst GJ, Swerdlow DI, van der Graaf Y, van Rij AM, Carey DJ, Elmore JR, Tromp G, Kuivaniemi H, Sayers RD, Samani NJ, Bown MJ, Humphries SE.

JAMA Cardiol. 2018 Jan 1;3(1):26-33. doi: 10.1001/jamacardio.2017.4293.

13.

Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials.

de Jong M, van der Worp HB, van der Graaf Y, Visseren FLJ, Westerink J.

Cardiovasc Diabetol. 2017 Oct 16;16(1):134. doi: 10.1186/s12933-017-0617-4. Review.

14.

Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial.

Koopal C, Marais AD, Westerink J, van der Graaf Y, Visseren FLJ.

J Lipid Res. 2017 Nov;58(11):2180-2187. doi: 10.1194/jlr.M076901. Epub 2017 Sep 19.

PMID:
28928170
15.

Incidence of cardiovascular events and vascular interventions in patients with type 2 diabetes.

Engelen SE, van der Graaf Y, Stam-Slob MC, Grobbee DE, Cramer MJ, Kappelle LJ, de Borst GJ, Visseren FLJ, Westerink J; SMART study group.

Int J Cardiol. 2017 Dec 1;248:301-307. doi: 10.1016/j.ijcard.2017.07.081. Epub 2017 Jul 23.

PMID:
28802735
16.

Relation between adiposity and vascular events, malignancy and mortality in patients with stable cerebrovascular disease.

Jaspers NEM, Dorresteijn JAN, van der Graaf Y, Westerink J, Kappelle LJ, Nathoe HM, Algra A, Visseren FLJ.

Int J Obes (Lond). 2017 Dec;41(12):1775-1781. doi: 10.1038/ijo.2017.184. Epub 2017 Aug 4.

PMID:
28775374
17.

SPRINT trial: It's not just the blood pressure!

Berkelmans GF, Visseren FL, Jaspers NE, Spiering W, van der Graaf Y, Dorresteijn JA.

Eur J Prev Cardiol. 2017 Sep;24(14):1482-1484. doi: 10.1177/2047487317723213. Epub 2017 Jul 27.

PMID:
28749177
18.

Physical Activity and Characteristics of the Carotid Artery Wall in High-Risk Patients-The SMART (Second Manifestations of Arterial Disease) Study.

Boss HM, van der Graaf Y, Visseren FLJ, Van den Berg-Vos RM, Bots ML, de Borst GJ, Cramer MJ, Kappelle LJ, Geerlings MI; SMART Study Group.

J Am Heart Assoc. 2017 Jul 23;6(7). pii: e005143. doi: 10.1161/JAHA.116.005143.

19.

Decline in risk of recurrent cardiovascular events in the period 1996 to 2014 partly explained by better treatment of risk factors and less subclinical atherosclerosis.

Berkelmans GFN, van der Graaf Y, Dorresteijn JAN, de Borst GJ, Cramer MJ, Kappelle LJ, Westerink J, Visseren FLJ; SMART study group.

Int J Cardiol. 2018 Jan 15;251:96-102. doi: 10.1016/j.ijcard.2017.07.026. Epub 2017 Jul 14.

20.

Risk Factors for Recurrent Cardiovascular Events Before Age 65 Years or Within 2.5 Years of a Recent First Cardiovascular Event.

van den Berg MJ, Westerink J, van der Graaf Y, Kappelle LJ, de Borst GJ, Cramer MM, Visseren FLJ; SMART study group.

Am J Cardiol. 2017 Jul 15;120(2):167-173. doi: 10.1016/j.amjcard.2017.04.002. Epub 2017 Apr 27.

PMID:
28532782
21.

Relation between Kidney Length and Cardiovascular and Renal Risk in High-Risk Patients.

van der Sande NGC, Visseren FLJ, van der Graaf Y, Nathoe HM, de Borst GJ, Leiner T, Blankestijn PJ; SMART Study Group.

Clin J Am Soc Nephrol. 2017 Jun 7;12(6):921-928. doi: 10.2215/CJN.08990816. Epub 2017 May 9.

22.

Detection and characterization of small infarcts in the caudate nucleus on 7 Tesla MRI: The SMART-MR study.

Ghaznawi R, de Bresser J, van der Graaf Y, Zwartbol MH, Witkamp TD, Geerlings MI, Hendrikse J; SMART Study Group * .

J Cereb Blood Flow Metab. 2017 Jan 1:271678X17705974. doi: 10.1177/0271678X17705974. [Epub ahead of print]

PMID:
28436255
23.

Identification of vascular patients at very high risk for recurrent cardiovascular events: validation of the current ACC/AHA very high risk criteria.

van den Berg MJ, Bhatt DL, Kappelle LJ, de Borst GJ, Cramer MJ, van der Graaf Y, Steg PG, Visseren FLJ; SMART study group; REACH Registry investigators.

Eur Heart J. 2017 Nov 14;38(43):3211-3218. doi: 10.1093/eurheartj/ehx102.

PMID:
28369481
24.

Response by Kaasenbrood et al to Letter Regarding Article, "Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population".

Kaasenbrood L, van der Graaf Y, Visseren FL.

Circulation. 2017 Mar 28;135(13):e820-e821. doi: 10.1161/CIRCULATIONAHA.117.027317. No abstract available.

25.

Relation of Epicardial Adipose Tissue Radiodensity to Coronary Artery Calcium on Cardiac Computed Tomography in Patients at High Risk for Cardiovascular Disease.

Franssens BT, Nathoe HM, Visseren FL, van der Graaf Y, Leiner T; SMART Study Group.

Am J Cardiol. 2017 May 1;119(9):1359-1365. doi: 10.1016/j.amjcard.2017.01.031. Epub 2017 Feb 11.

PMID:
28279438
26.

Cost-Effectiveness of Intensifying Lipid-Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients.

Stam-Slob MC, van der Graaf Y, Greving JP, Dorresteijn JA, Visseren FL.

J Am Heart Assoc. 2017 Feb 18;6(2). pii: e004648. doi: 10.1161/JAHA.116.004648.

27.

Do Lacunar Infarcts Have Different Aetiologies? Risk Factor Profiles of Lacunar Infarcts in Deep White Matter and Basal Ganglia: The Second Manifestations of ARTerial Disease-Magnetic Resonance Study.

Kloppenborg RP, Nederkoorn PJ, Grool AM, De Cocker LJ, Mali WP, van der Graaf Y, Geerlings MI; SMART Study Group.

Cerebrovasc Dis. 2017;43(3-4):161-168. doi: 10.1159/000454782. Epub 2017 Jan 31.

28.

Relation between brown adipose tissue and measures of obesity and metabolic dysfunction in patients with cardiovascular disease.

Franssens BT, Hoogduin H, Leiner T, van der Graaf Y, Visseren FLJ.

J Magn Reson Imaging. 2017 Aug;46(2):497-504. doi: 10.1002/jmri.25594. Epub 2017 Jan 27.

PMID:
28130811
29.

High ratios of kidney function to kidney size are related to mortality and kidney function decline in high-risk patients.

van der Sande NG, Blankestijn PJ, Leiner T, van der Graaf Y, de Borst GJ, Cramer MJ, Visseren FL; SMART study group.

Eur J Prev Cardiol. 2017 Jun;24(9):926-933. doi: 10.1177/2047487317690950. Epub 2017 Jan 25.

PMID:
28121180
30.

Automatic Coronary Artery Calcium Scoring on Radiotherapy Planning CT Scans of Breast Cancer Patients: Reproducibility and Association with Traditional Cardiovascular Risk Factors.

Gernaat SA, Išgum I, de Vos BD, Takx RA, Young-Afat DA, Rijnberg N, Grobbee DE, van der Graaf Y, de Jong PA, Leiner T, van den Bongard DH, Pignol JP, Verkooijen HM.

PLoS One. 2016 Dec 9;11(12):e0167925. doi: 10.1371/journal.pone.0167925. eCollection 2016.

31.

The Effects of Secondary Cardiovascular Prevention on Cancer Risk in Patients With Manifest Vascular Disease.

van Kruijsdijk RC, van der Graaf Y, Algra A, de Borst GJ, Cramer MJ, Siersema PD, Peeters PH, Visseren FL; SMART study group.

J Am Coll Cardiol. 2016 Dec 13;68(23):2588-2589. doi: 10.1016/j.jacc.2016.09.950. No abstract available.

32.

Relation between cardiovascular disease risk factors and epicardial adipose tissue density on cardiac computed tomography in patients at high risk of cardiovascular events.

Franssens BT, Nathoe HM, Leiner T, van der Graaf Y, Visseren FL; SMART study group.

Eur J Prev Cardiol. 2017 Apr;24(6):660-670. doi: 10.1177/2047487316679524. Epub 2016 Jan 1.

PMID:
27872327
33.

Effect modification in the association between glycated haemoglobin and cardiovascular disease and mortality in patients with type 2 diabetes.

van Munster SN, van der Graaf Y, de Valk HW, Visseren FL, Westerink J; SMART Study Group.

Diabetes Obes Metab. 2017 Mar;19(3):320-328. doi: 10.1111/dom.12820. Epub 2016 Dec 28.

PMID:
27807924
34.

Hippocampal volume and the course of depressive symptoms over eight years of follow-up.

Buddeke J, Kooistra M, Zuithoff NP, Gerritsen L, Biessels GJ, van der Graaf Y, Geerlings MI; SMART Study Group.

Acta Psychiatr Scand. 2017 Jan;135(1):78-86. doi: 10.1111/acps.12662. Epub 2016 Nov 1.

PMID:
27800603
35.

Chronic hyperglycemia is related to poor functional outcome after acute ischemic stroke.

Luitse MJ, Velthuis BK, Kappelle LJ, van der Graaf Y, Biessels GJ; DUST Study Group.

Int J Stroke. 2017 Feb;12(2):180-186. doi: 10.1177/1747493016676619. Epub 2016 Oct 26.

PMID:
27784821
36.

Determinants of leptomeningeal collateral flow in stroke patients with a middle cerebral artery occlusion.

van Seeters T, Biessels GJ, Kappelle LJ, van der Graaf Y, Velthuis BK; Dutch acute stroke study (DUST) investigators.

Neuroradiology. 2016 Oct;58(10):969-977. Epub 2016 Jul 20.

37.

Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population.

Kaasenbrood L, Boekholdt SM, van der Graaf Y, Ray KK, Peters RJ, Kastelein JJ, Amarenco P, LaRosa JC, Cramer MJ, Westerink J, Kappelle LJ, de Borst GJ, Visseren FL.

Circulation. 2016 Nov 8;134(19):1419-1429. Epub 2016 Sep 28.

38.

Response to Comment on Sharif et al. HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. Diabetes Care 2016;39:1424-1430.

Sharif S, van der Graaf Y, Nathoe HM, de Valk HW, Visseren FL, Westerink J; SMART Study Group.

Diabetes Care. 2016 Oct;39(10):e190-1. doi: 10.2337/dci16-0023. No abstract available.

PMID:
27660133
39.

Adapting clinical guidelines in low-resources countries: a study on the guideline on the management and prevention of type 2 diabetes mellitus in Indonesia.

Widyahening IS, Wangge G, van der Graaf Y, van der Heijden GJ.

J Eval Clin Pract. 2017 Feb;23(1):121-127. doi: 10.1111/jep.12628. Epub 2016 Sep 4.

40.

Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.

van der Leeuw J, Visseren FL, Woodward M, van der Graaf Y, Grobbee DE, Harrap S, Heller S, Mancia G, Marre M, Poulter N, Zoungas S, Chalmers J.

Diabetologia. 2016 Dec;59(12):2603-2612. Epub 2016 Sep 1.

41.

Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients.

Stam-Slob MC, Visseren FL, Wouter Jukema J, van der Graaf Y, Poulter NR, Gupta A, Sattar N, Macfarlane PW, Kearney PM, de Craen AJ, Trompet S.

Clin Res Cardiol. 2017 Jan;106(1):58-68. doi: 10.1007/s00392-016-1023-8. Epub 2016 Aug 23.

42.

Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, Triglycerides, and Apolipoprotein B and Cardiovascular Risk in Patients With Manifest Arterial Disease.

van den Berg MJ, van der Graaf Y, de Borst GJ, Kappelle LJ, Nathoe HM, Visseren FLJ; SMART Study Group.

Am J Cardiol. 2016 Sep 15;118(6):804-810. doi: 10.1016/j.amjcard.2016.06.048. Epub 2016 Jun 28.

43.

Metabolic consequences of adipose tissue dysfunction and not adiposity per se increase the risk of cardiovascular events and mortality in patients with type 2 diabetes.

Franssens BT, Westerink J, van der Graaf Y, Nathoe HM, Visseren FLJ; SMART study group.

Int J Cardiol. 2016 Nov 1;222:72-77. doi: 10.1016/j.ijcard.2016.07.081. Epub 2016 Jul 5.

PMID:
27458826
44.

The influence of baseline risk on the relation between HbA1c and risk for new cardiovascular events and mortality in patients with type 2 diabetes and symptomatic cardiovascular disease.

Bots SH, van der Graaf Y, Nathoe HM, de Borst GJ, Kappelle JL, Visseren FL, Westerink J; SMART Study Group.

Cardiovasc Diabetol. 2016 Jul 19;15(1):101. doi: 10.1186/s12933-016-0418-1.

45.

Individualized prediction of the effect of angiotensin receptor blockade on renal and cardiovascular outcomes in patients with diabetic nephropathy.

van der Sande NG, Dorresteijn JA, Visseren FL, Dwyer JP, Blankestijn PJ, van der Graaf Y, Heerspink HL.

Diabetes Obes Metab. 2016 Nov;18(11):1120-1127. doi: 10.1111/dom.12708. Epub 2016 Aug 12.

PMID:
27337598
46.

Poor Performance Among Trainees in a Dutch Postgraduate GP Training Program.

Vermeulen MI, Kuyvenhoven MM, de Groot E, Zuithoff NP, Pieters HM, van der Graaf Y, Damoiseaux RA.

Fam Med. 2016 Jun;48(6):430-8.

47.

The natural course of elevated levels of depressive symptoms in patients with vascular disease over eight years of follow-up. The SMART-Medea study.

Kooistra M, van der Graaf Y, Grool AM, Zuithoff NP, Jan Biessels G, Geerlings MI; SMART-MR Study Group.

J Affect Disord. 2016 Sep 15;202:95-101. doi: 10.1016/j.jad.2016.05.050. Epub 2016 May 24.

PMID:
27259081
48.

Novel Biomarkers to Improve the Prediction of Cardiovascular Event Risk in Type 2 Diabetes Mellitus.

van der Leeuw J, Beulens JW, van Dieren S, Schalkwijk CG, Glatz JF, Hofker MH, Verschuren WM, Boer JM, van der Graaf Y, Visseren FL, Peelen LM, van der Schouw YT.

J Am Heart Assoc. 2016 May 31;5(6). pii: e003048. doi: 10.1161/JAHA.115.003048.

49.

HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes.

Sharif S, van der Graaf Y, Nathoe HM, de Valk HW, Visseren FL, Westerink J; SMART Study Group.

Diabetes Care. 2016 Aug;39(8):1424-30. doi: 10.2337/dc16-0155. Epub 2016 May 23.

PMID:
27222511
50.

Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study.

Kaasenbrood L, Poulter NR, Sever PS, Colhoun HM, Livingstone SJ, Boekholdt SM, Pressel SL, Davis BR, van der Graaf Y, Visseren FL; CARDS, ALLHAT, and ASCOT Investigators.

Circ Cardiovasc Qual Outcomes. 2016 May;9(3):213-21. doi: 10.1161/CIRCOUTCOMES.115.001980. Epub 2016 May 11.

Supplemental Content

Loading ...
Support Center